$TDOCNeutralLow

Catapano Joseph Ronald sold $2K of TDOC

Catapano Joseph Ronald (Chief Accounting Officer) sold 284 shares of Teladoc Health, Inc. (TDOC) at $7.63 on 2026-06-02.

4/10
6/10
Low
Neutral
Filed after-hours on 2026-06-03; reflects sale dated 2026-06-02.
Generally neutral; insider selling can be interpreted cautiously but is not a new fundamental catalyst.

Insider sale is a small, non-10b5-1-plan transaction; it may be viewed as mild negative/neutral but is unlikely to be fundamental.

Teladoc Health CAO sold 284 shares in an open-market transaction, disclosing a direct insider ownership change on SEC Form 4.

Low likelihood of a sustained price move; any reaction is likely limited and sentiment-driven.

Background

SEC Form 4 reports insider transactions by officers/directors/10% owners; this one is an open-market sale by Teladoc’s Chief Accounting Officer.

Why it matters

The disclosed sale can slightly influence sentiment, but without accompanying corporate news it is unlikely to materially change valuation assumptions.

Market relevance

Traders may monitor for follow-on insider activity, but this specific filing alone is not a strong catalyst.

Market effects

Minimal; single-company Form 4 insider sale typically does not reset sector expectations.

None indicated.

None indicated.

Alternative perspectives

A non-10b5-1-plan sale can be driven by diversification/taxes rather than bearish fundamentals, especially at small size.

The article provides only the sale details; it does not include context like prior grants, compensation timing, or whether other insiders simultaneously bought/sold.

Key entities

  • Teladoc Health, Inc.

    Subject of the insider transaction disclosure (Form 4) involving an officer sale.

  • Catapano Joseph Ronald

    Chief Accounting Officer who sold 284 shares at $7.6270 on 2026-06-02.

Related articles

$TDOCMedAI 8/10

TDOC Stock Pops as Teladoc Teams Up With Walmart

Barchart reports that Teladoc Health’s consensus rating remains “Moderate Buy,” with a mean price target of $7.24, suggesting limited additional upside versus current levels. The stock rose after Teladoc announced a partnership with Walmart, according to the article.

$TDOCMedAI 8/10

Could This Beaten‑Down Stock Be a Millionaire‑Maker Over the Next Decade?

Teladoc Health’s stock has fallen more than 90% over five years, and the company remains unprofitable. In Q1, revenue fell 2% year over year to $613.8 million and net loss per share improved to $0.36, but a 2025 goodwill impairment charge hurt results. BetterHelp revenue and paying users declined 9% y/y, while international revenue rose 17% to $122.3 million.